Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Looks Beyond First-In-Class Only As It Seeks To Bolster R&D Productivity

Executive Summary

With three large outcomes studies to read out interim or final results, 2012 is likely to be a pivotal year for Merck’s R&D, even as it rebalances its traditionally first-in-class emphasis to a hybrid model that also embraces best in class.

You may also be interested in...



MSD India Managing Director K.G. Ananthakrishnan On Disease Management And Taking A Holistic Approach: An Interview With PharmAsia News (Part 2 of 2)

Merck Sharp & Dohme India Managing Director K.G. Ananthakrishnan discusses MSD’s holistic approach to patient care in India, including disease management, physician education and responsible pricing.

Merck Launches FosaMax Plus In China; More Launches For Diabetes And Cardiovascular Drugs Expected

Following Eli Lilly’s launch of Forteo in China last November, Merck is launching FosaMax Plus, a vitamin D compounded version of its osteoporosis blockbuster FosaMax.

Diabetes Franchise May Help Merck Offset Loss Of Singulair

The Januvia/Janumet franchise posted sales growth of 40% both in the fourth quarter and over the full year for Merck, while Isentress and Gardasil also posted strong growth rates.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS053973

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel